Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

ClinicalTrials.gov ID: NCT05268016

Public ClinicalTrials.gov record NCT05268016. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 27, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects With Moderate to Severe Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.

Study identification

NCT ID
NCT05268016
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Meiji Pharma USA Inc.
Industry
Enrollment
132 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 23, 2022
Primary completion
May 30, 2023
Completion
May 30, 2023
Last update posted
Jun 26, 2024

2022 – 2023

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
Northwest Arkansas Clinical Trials Center Rogers Arkansas 72758 —
University of Southern California Los Angeles California 90033 —
Colorado Medical Research Center, Inc. Denver Colorado 80210 —
International Dermatology Research, INC Miami Florida 33144 —
Qualmedica Research, LLC Evansville Indiana 47715 —
Owensboro Dermatology Associates Owensboro Kentucky 42303 —
Shondra L. Smith, MD Dermatology & Advanced Aesthetics Lake Charles Louisiana 70605 —
Skin Search of Rochester, Inc. Rochester New York 14623 —
Tennessee Clinical Research Center Nashville Tennessee 37215 —
Studies in Dermatology, LLC Cypress Texas 77433 —
Dermatology Treatment and Research Center Dallas Texas 75230 —
Center for Clinical Studies LTD, LLP Houston Texas 77004 —
Dermatology Clinical Research Center of San Antonio San Antonio Texas 78229 —
Premier Clinical Research Spokane Washington 99202 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05268016, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 26, 2024 · Synced Sep 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05268016 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →